To read the full story
Related Article
- Chuikyo Agrees to Vet Conditional Scheme for Regenerative Medicine as Elevidys Gets Approval
May 15, 2025
- Chuikyo Urges Rethink of Health Coverage for Conditionally Approved Regenerative Medicines
August 9, 2024
- Terumo to End Sale of HeartSheet after Panel’s Thumbs-Down
July 22, 2024
- Japan Panel Says No to Full Approval of HeartSheet, Clears Breyanzi’s Broader Label
July 22, 2024
- AnGes Alters Strategy for Collategene, Halts Japan Sales for Fresh Submission
June 25, 2024
REGULATORY
- LDP Project Team Eyes Coverage Discussions for Drug Use in Pre-Symptomatic Stage
May 20, 2025
- New Stelara Biosimilars Earn May Listing, Eylea Follow-On Takes Pass Again
May 20, 2025
- Japan Approves Moderna RSV Vaccine, GSK’s ADC, and More
May 20, 2025
- Ex-Lawmakers’ Club Proposes CEA Overhaul, GDP-Linked Drug Spending
May 16, 2025
- Ex-PM Kishida Stresses Need to Bolster Innovation in Japan: Tokyo Speech
May 16, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…